Discovery of a novel class of targeted kinase inhibitors that blocks protein kinase C signaling and ameliorates retinal vascular leakage in a diabetic rat model

European Journal of Pharmacology

Volumn 627, Issue 1-3, 2010, Pages 16-25

  Grant, Stephan ^a   Tran, Phong ^a   Zhang, Qin ^a   Zou, Aihua ^a   Dinh, Dac ^a   Jensen, Jordan ^a   Zhou, Sue ^a   Kang, Xiaolin ^a   Zachwieja, Joseph ^a   Lippincott, John ^a   Liu, Kevin ^a   Johnson, Sarah Ludlum ^a   Scales, Stephanie ^a   Yin, Chunfeng ^a   Nukui, Seiji ^a   Stoner, Chad ^a   Prasanna, Ganesh ^a   Lafontaine, Jennifer ^a   Wells, Peter ^a   Li, Hui ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Diabetic complication; Diabetic retinopathy; Drug discovery; PKC inhibitor; Protein kinase C; Signal transduction

Indexed keywords

3 AMINO 6,6 DIMETHYL 1,4,5,6 TETRAHYDROPYRROLO[3,4 C]PYRAZOLE DERIVATIVE; ADENOSINE TRIPHOSPHATE; PF 03323892; PF 03622905; PF 04577806; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STRUCTURE ANALYSIS; TREATMENT DURATION;

ADMINISTRATION, ORAL; ANIMALS; CATTLE; CELL LINE; DIABETES COMPLICATIONS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; MALE; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS; PYRAZOLES; RATS; RETINAL DISEASES; RETINAL VESSELS; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 73449091461     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.029     Document Type: Article

References (50)

1. Aiello L.P., Clermont A., Arora V., Davis M.D., Sheetz M.J., and Bursell S.E. Inhibition of PKCβ by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest. Ophthalmol. Vis. Sci. 47 (2006) 86-92
2. Bit R.A., Davis P.D., Elliott L.H., Harris W., Hill C.H., Keech E., Kumar H., Lawton G., Maw A., Nixon J.S., Vesey D.R., Wadsworth J., and Wilkinson S.E. Inhibitors of protein kinase C. 3. Potent and highly selective bisindolylmaleimides by conformational restriction. J. Med. Chem. 26 (1993) 21-29
3. Botrous I., Hong Y., Li H., Liu K.K.-C., Nukui S., Teng M., Tompkins E.V., and Yin C.-F. Novel 3-amino-pyrrolo[3,4-c]pyrazole-5(1H, 4H, 6H) carbaldehyde derivatives. WO 2008/125945 A2 (2008)
4. Brasca M.G., Albanese C., Amici R., Ballinari D., Corti L., Croci V., Fancelli D., Fiorentini F., Nesi M., Orsini P., Orzi F., Pastori W., Perrone E., Pesenti E., Pevarello P., Riccardi-Sirtori F., Roletto F., Roussel P., Varasi M., Vulpetti A., and Mercurio C. 6-Substituted pyrrolo[3, 4-c]pyrazoles: an improved class of CDK2 inhibitors. Chem. Med. Chem. 2 (2007) 841-852
5. Campochiaro P.A., and C99-PKC412-003 Study Group. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest. Ophthalmol. Vis. Sci. 45 (2004) 922-931
6. Carpinelli P., and Moll J. Aurora kinase inhibitors: identification and preclinical validation of their biomarkers. Expert Opin. Ther. Targets 12 (2008) 69-80
7. Carpinelli P., Ceruti R., Giorgini M.L., Cappella P., Gianellini L., Croci V., Degrassi A., Texido G., Rocchetti M., Vianello P., Rusconi L., Storici P., Zugnoni P., Arrigoni C., Soncini C., Alli C., Patton V., Marsiglio A., Ballinari D., Pesenti E., Fancelli D., and Moll J. PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer. Mol. Cancer Ther. 6 (2007) 3158-3168
8. Copeland R.A. Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists (2005), John Wiley and Sons, Hoboken, NJ 51-63
9. Das Evcimen N., and King G.L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol. Res. 55 (2007) 498-510
10. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
11. Elling R.A., Fucini R.V., and Romanowski M.J. Structures of the wild-type and activated catalytic domains of Brachydanio rerio polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands. Acta Crystallogr. D64 (2008) 909-918
12. Fabbro D., Buchdunger E., Wood J., Mestan J., Hofmann F., Ferrari S., Mett H., O'Reilly T., and Meyer T. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol. Ther. 82 (1999) 293-301
13. Fabian M.A., Biggs III W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., Ford J.M., Galvin M., Gerlach J.L., Grotzfeld R.M., Herrgard S., Insko D.E., Insko M.A., Lai A.G., Lélias J.M., Mehta S.A., Milanov Z.V., Velasco A.M., Wodicka L.M., Patel H.K., Zarrinkar P.P., and Lockhart D.J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23 (2005) 329-336
14. Fancelli D., Berta D., Bindi S., Cameron A., Cappella P., Carpinelli P., Catana C., Forte B., Giordano P., Giorgini M.L., Mantegani S., Marsiglio A., Meroni M., Moll J., Pittalà V., Roletto F., Severino D., Soncini C., Storici P., Tonani R., Varasi M., Vulpetti A., and Vianello P. Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition. J. Med. Chem. 48 (2005) 3080-3084
15. Fancelli D., Moll J., Varasi M., Bravo R., Artico R., Berta D., Bindi S., Cameron A., Candiani I., Cappella P., Carpinelli P., Croci W., Forte B., Giorgini M.L., Klapwijk J., Marsiglio A., Pesenti E., Rocchetti M., Roletto F., Severino D., Soncini C., Storici P., Tonani R., Zugnoni P., and Vianello P. 1, 4, 5, 6-tetrahydropyrrolo[3, 4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile. J. Med. Chem. 49 (2006) 7247-7251
16. Fedorov O., Marsden B., Pogacic V., Rellos P., Müller S., Bullock A.N., Schwaller J., Sundström M., and Knapp S. A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 20523-20528
17. Gescher A. Staurosporine analogues - pharmacological toys or useful antitumour agents?. Crit. Rev. Oncol. Hematol. 34 (2000) 127-135
18. Gontarewicz A., Balabanov S., Keller G., Colombo R., Graziano A., Pesenti E., Benten D., Bokemeyer C., Fiedler W., Moll J., and Brümmendorf T.H. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111 (2008) 4355-4364
19. Gould G.M., and Newton A.C. The life and death of protein kinase C. Current Drug Targets 9 (2008) 614-625
20. Grodsky N., Li Y., Bouzida D., Love R., Jensen J., Nodes B., Nonomiya J., and Grant S. Structure of the catalytic domain of human protein kinase C beta II complexed with a bisindolylmaleimide inhibitor. Biochemistry 45 (2006) 13970-13981
21. Ishii H., Jirousek M.R., Koya D., Takagi C., Xia P., Clermont A., Bursell S.E., Kern T.S., Ballas L.M., Heath W.F., Stramm L.E., Feener E.P., and King G.L. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272 (1996) 728-731
22. Jirousek M.R., Gillig J.R., Gonzalez C.M., Heath W.F., McDonald III J.H., Neel D.A., Rito C.J., Singh U., Stramm L.E., Melikian-Badalian A., Baevsky M., Ballas L.M., Hall S.E., Winneroski L.L., and Faul M.M. (S)-13-[(dimethylamino)methyl]-10, 11, 14, 15-tetrahydro-4, 9:16, 21-dimetheno-1H, 13H-dibenzo[e, k]pyrrolo[3, 4-h][1, 4, 13]oxadiazacyclohexadecene-1, 3(2H)-dione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta. J. Med. Chem. 39 (1996) 2664-2671
23. Joy S.V., Scates A.C., Bearelly S., Dar M., Taulien C.A., Goebel J.A., and Cooney M.J. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications. Ann. Pharmacother. 39 (2005) 1693-1699
24. Karaman M.W., Herrgard S., Treiber D.K., Gallant P., Atteridge C.E., Campbell B.T., Chan K.W., Ciceri P., Davis M.I., Edeen P.T., Faraoni R., Floyd M., Hunt J.P., Lockhart D.J., Milanov Z.V., Morrison M.J., Pallares G., Patel H.K., Pritchard S., Wodicka L.M., and Zarrinkar P.P. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26 (2008) 127-132
25. Karima M., Kantarci A., Ohira T., Hasturk H., Jones V.L., Nam B.H., Malabanan A., Trackman P.C., Badwey J.A., and Van Dyke T.E. Enhanced superoxide release and elevated protein kinase C activity in neutrophils from diabetic patients: association with periodontitis. J. Leukoc. Biol. 78 (2005) 862-870
26. Kothe M., Kohls D., Low S., Coli R., Cheng A.C., Jacques S.L., Johnson T.L., Lewis C., Loh C., Nonomiya J., Sheils A.L., Verdries K.A., Wynn T.A., Kuhn C., and Ding Y.H. Structure of the catalytic domain of human polo-like kinase 1. Biochemistry 46 (2007) 5960-5971
27. Kowluru R.A., Jirousek M.R., Stramm L., Farid N., Engerman R.L., and Kern T.S. Abnormalities of retinal metabolism in diabetes or experimental galactosemia: V. Relationship between protein kinase C and ATPases. Diabetes 47 (1998) 464-469
28. Li Y.Q., Hii C.S., Costabile M., Goh D., Der C.J., and Ferrante A. Regulation of lymphotoxin production by the p21ras-raf-MEK-ERK cascade in PHA/PMA-stimulated Jurkat cells. J. Immunol. 162 (1999) 3316-3320
29. Martiny-Baron G., Kazanietz M.G., Mischak H., Blumberg P.M., Kochs G., Hug H., Marmé D., and Schächtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J. Biol. Chem. 268 (1993) 9194-9197
30. Meier M., Menne J., Park J.-K., and Haller H. Nailing down PKC isoform specificity in diabetic nephropathy - two's company, three's a crowd. Nephrol. Dial. Transplant. 22 (2007) 2421-2425
31. Millward M.J., House C., Bowtell D., Webster L., Olver I.N., Gore M., Copeman M., Lynch K., Yap A., Wang Y., Cohen P.S., and Zalcberg J. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. Br. J. Cancer 95 (2006) 829-834
32. Modugno M., Casale E., Soncini C., Rosettani P., Colombo R., Lupi R., Rusconi L., Fancelli D., Carpinelli P., Cameron A.D., Isacchi A., and Moll J. Crystal structure of the T315I Abl mutant in complex with the Aurora kinases inhibitor PHA-739358. Cancer Res. 67 (2007) 7987-7990
33. Newton A.C. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem. Rev. 101 (2001) 2353-2364
34. Park J.Y., Takahara N., Gabriele A., Chou E., Naruse K., Suzuma K., Yamauchi T., Ha S.W., Meier M., Rhodes C.J., and King G.L. Induction of endothelin-1 expression by glucose: an effect of protein kinase C activation. Diabetes 49 (2000) 1239-1248
35. Pevarello P., Fancelli D., Vulpetti A., Amici R., Villa M., Pittalà V., Vianello P., Cameron A., Ciomei M., Mercurio C., Bischoff J.R., Roletto F., Varasi M., and Brasca M.G. 3-Amino-1, 4, 5, 6-tetrahydropyrrolo[3, 4-c]pyrazoles: a new class of CDK2 inhibitors. Bioorg. Med. Chem. Lett. 16 (2006) 1084-1090
36. Quintas-Cardama A., and Cortes J. Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia. Clin. Cancer Res. 14 (2008) 4392-4399
37. Soncini C., Carpinelli P., Gianellini L., Fancelli D., Vianello P., Rusconi L., Storici P., Zugnoni P., Pesenti E., Croci V., Ceruti R., Giorgini M.L., Cappella P., Ballinari D., Sola F., Varasi M., Bravo R., and Moll J. PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin. Cancer Res. 12 (2006) 4080-4089
38. Sridhar J., and Pattabiraman N. Synthesis and isozyme selectivity of small molecule protein kinase C inhibitors: a review of patents. Expert Opin. Ther. Pat. 15 (2005) 1691-1701
39. Strack V., Krützfeldt J., Kellerer M., Ullrich A., Lammers R., and Häring H.U. The protein-tyrosine-phosphatase SHP2 is phosphorylated on serine residues 576 and 591 by protein kinase C isoforms alpha, beta 1, beta 2, and eta. Biochemistry 41 (2002) 603-608
40. Strøm C., Sander B., Klemp K., Aiello L.P., Lund-Andersen H., and Larsen M. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 46 (2005) 3855-3858
41. Suzuma K., Takahara N., Suzuma I., Isshiki K., Ueki K., Leitges M., Aiello L.P., and King G.L. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 721-726
42. Talele T.T., and McLaughlin M.L. Molecular docking/dynamics studies of Aurora A kinase inhibitors. J. Mol. Graph. Model 26 (2008) 1213-1222
43. Tanaka M., Sagawa S., Hoshi J., Shimoma F., Yasue K., Ubukata M., Ikemoto T., Hase Y., Takahashi M., Sasase T., Ueda N., Matsushita M., and Inaba T. Synthesis, SAR studies, and pharmacological evaluation of 3-anilino-4-(3-indolyl) maleimides with conformationally restricted structure as orally bioavailable PKCbeta-selective inhibitors. Bioorg. Med. Chem. 14 17 (2006) 5781-5794
44. The PKC-DMES Study Group, Aiello L.P., Davis M.D., Girach A., Hu K., Milton R.C., Sheetz M.J., and aVignati L. Effect of ruboxistaurin in patients with diabetic macular edema. Arch. Ophthalmol. 125 (2007) 318-324
45. The PKC-DRS Study Group. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial. Diabetes 54 (2005) 2188-2197
46. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., Baudet V., Boissin P., Boursier E., Loriolle F., Duhamel L., Charon D., and Kirilovsky J. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266 (1991) 15771-15781
47. Vinik A. The protein kinase C-beta inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications. Expert Opin. Investig. Drugs 14 (2005) 1547-1559
48. Winkler B.S. The electroretinogram of the isolated rat retina. Vision Res. 12 (1972) 1183-1198
49. Xu Q., Qaum T., and Adamis A.P. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest. Ophthalmol. Vis. Sci. 4 (2001) 789-794
50. Zhang H.C., White K.B., Ye H., McComsey D.F., Derian C.K., Addo M.F., Andrade-Gordon P., Eckardt A.J., Conway B.R., Westover L., Xu J.Z., Look R., Demarest K.T., Emanuel S., and Maryanoff B.E. Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. Bioorg. Med. Chem. Lett. 13 (2003) 3049-3053